A safe and broad-spectrum SARS-CoV-2 mRNA vaccine with a new delivery system for in-situ expression.

ABSTRACT: Since the outbreak of COVID-19 in late 2019, the cumulative number of confirmed cases worldwide has surpassed 778 million, and the number of deaths has exceeded 7 million, posing a significant threat to human life and health while inflicting enormous losses on the global economy. At the stage where sequential immunization is recommended, there is a pressing demand for mRNA vaccines that can be rapidly adapted to new sequences, are easy to industrialize, and exhibit high safety and effectiveness. We developed a lipid nanoparticle (LNP) system, designated as WNP, which facilitates essentially in situ expression at the injection site and results in lower levels of pro-inflammatory factors in the liver, thus enhancing its safety compared to liver-targeted alternatives. Furthermore, in light of

SUBMITTER: Yu W 

PROVIDER: S-EPMC12665414 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature